Literature DB >> 20702667

Rapid drug susceptibility testing with a molecular beacon assay is associated with earlier diagnosis and treatment of multidrug-resistant tuberculosis in California.

Ritu Banerjee1, Jennifer Allen, S-Y Grace Lin, Janice Westenhouse, Ed Desmond, Gisela F Schecter, Cheryl Scott, Ann Raftery, Sundari Mase, James P Watt, Jennifer Flood.   

Abstract

To assess the clinical impact of a molecular beacon (MB) assay that detects multidrug-resistant tuberculosis (MDR TB), we retrospectively reviewed records of 127 MDR TB patients with and without MB testing between 2004 and 2007. Use of the MB assay reduced the time to detection and treatment of MDR TB.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20702667      PMCID： PMC2953075          DOI： 10.1128/JCM.01236-10

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  7 in total

1.  Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs--worldwide, 2000-2004.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2006-03-24       Impact factor: 17.586

2.  Molecular beacon sequence analysis for detecting drug resistance in Mycobacterium tuberculosis.

Authors:  A S Piatek; S Tyagi; A C Pol; A Telenti; L P Miller; F R Kramer; D Alland
Journal:  Nat Biotechnol       Date:  1998-04       Impact factor: 54.908

3.  Evaluation of a line probe assay kit for characterization of rpoB mutations in rifampin-resistant Mycobacterium tuberculosis isolates from New York City.

Authors:  R C Cooksey; G P Morlock; S Glickman; J T Crawford
Journal:  J Clin Microbiol       Date:  1997-05       Impact factor: 5.948

4.  Characteristics of patients with delayed diagnosis of infectious pulmonary tuberculosis.

Authors:  Lee-Lan Phoa; Monica D Teleman; Yee-Tang Wang; Cynthia B E Chee
Journal:  Respirology       Date:  2005-03       Impact factor: 6.424

5.  Delay in diagnosis among hospitalized patients with active tuberculosis--predictors and outcomes.

Authors:  Christina Greenaway; Dick Menzies; Anne Fanning; Raj Grewal; Lilian Yuan; J Mark FitzGerald
Journal:  Am J Respir Crit Care Med       Date:  2002-04-01       Impact factor: 21.405

6.  Increasing proportions of advanced pulmonary tuberculosis reported in the United States: are delays in diagnosis on the rise?

Authors:  Ryan Maclaren Wallace; J Steve Kammerer; Michael F Iademarco; Sandy P Althomsons; Carla A Winston; Thomas R Navin
Journal:  Am J Respir Crit Care Med       Date:  2009-08-13       Impact factor: 21.405

7.  Rapid detection of isoniazid and rifampin resistance mutations in Mycobacterium tuberculosis complex from cultures or smear-positive sputa by use of molecular beacons.

Authors:  S-Y Grace Lin; William Probert; Melanie Lo; Edward Desmond
Journal:  J Clin Microbiol       Date:  2004-09       Impact factor: 5.948
  7 in total
  11 in total

1.  Pyrosequencing for rapid detection of extensively drug-resistant Mycobacterium tuberculosis in clinical isolates and clinical specimens.

Authors:  S-Y Grace Lin; Timothy C Rodwell; Thomas C Victor; Errin C Rider; Lucy Pham; Antonino Catanzaro; Edward P Desmond
Journal:  J Clin Microbiol       Date:  2013-11-27       Impact factor: 5.948

2.  The California Multidrug-Resistant Tuberculosis Consult Service: a partnership of state and local programs.

Authors:  N S Shah; J Westenhouse; P Lowenthal; G Schecter; L True; S Mase; P M Barry; J Flood
Journal:  Public Health Action       Date:  2018-03-21

3.  Impact of rapid drug susceptibility testing for tuberculosis: program experience in Lima, Peru.

Authors:  S S Shin; L Asencios; M Yagui; G Yale; C Suárez; J Bayona; C Bonilla; O Jave; C C Contreras; S Atwood; J A Blaya; J Ershova; J P Cegielski
Journal:  Int J Tuberc Lung Dis       Date:  2012-09-14       Impact factor: 2.373

Review 4.  Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review.

Authors:  Sophia B Georghiou; Marisa Magana; Richard S Garfein; Donald G Catanzaro; Antonino Catanzaro; Timothy C Rodwell
Journal:  PLoS One       Date:  2012-03-29       Impact factor: 3.240

5.  Targeted drug-resistance testing strategy for multidrug-resistant tuberculosis detection, Lima, Peru, 2005-2008.

Authors:  Gustavo E Velásquez; Martin Yagui; J Peter Cegielski; Luis Asencios; Jaime Bayona; Cesar Bonilla; Hector O Jave; Gloria Yale; Carmen Suárez; Sidney Atwood; Carmen C Contreras; Sonya S Shin
Journal:  Emerg Infect Dis       Date:  2011-03       Impact factor: 6.883

Review 6.  Evaluation of tuberculosis diagnostics: establishing an evidence base around the public health impact.

Authors:  Richard J Lessells; Graham S Cooke; Marie-Louise Newell; Peter Godfrey-Faussett
Journal:  J Infect Dis       Date:  2011-11-15       Impact factor: 5.226

7.  Self-reported risks for multiple-drug resistance among new tuberculosis cases: implications for drug susceptibility screening and treatment.

Authors:  Timothy F Brewer; Howard W Choi; Carlos Seas; Fiorella Krapp; Carlos Zamudio; Lena Shah; Antonio Ciampi; S Jody Heymann; Eduardo Gotuzzo
Journal:  PLoS One       Date:  2011-10-14       Impact factor: 3.240

8.  Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005-2007.

Authors:  Suzanne M Marks; Jennifer Flood; Barbara Seaworth; Yael Hirsch-Moverman; Lori Armstrong; Sundari Mase; Katya Salcedo; Peter Oh; Edward A Graviss; Paul W Colson; Lisa Armitige; Manuel Revuelta; Kathryn Sheeran
Journal:  Emerg Infect Dis       Date:  2014-05       Impact factor: 6.883

9.  Clinical Impact on Tuberculosis Treatment Outcomes of Discordance Between Molecular and Growth-Based Assays for Rifampin Resistance, California 2003-2013.

Authors:  Neha S Shah; S Y Grace Lin; Pennan M Barry; Yi-Ning Cheng; Gisela Schecter; Ed Desmond
Journal:  Open Forum Infect Dis       Date:  2016-08-24       Impact factor: 3.835

10.  Multi-Fluorescence Real-Time PCR Assay for Detection of RIF and INH Resistance of M. tuberculosis.

Authors:  Jingfu Peng; Xiaoli Yu; Zhenling Cui; Wenfei Xue; Ziyi Luo; Zilu Wen; Minghua Liu; Danqing Jiang; Heping Zheng; Hai Wu; Shulin Zhang; Yao Li
Journal:  Front Microbiol       Date:  2016-04-29       Impact factor: 5.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.